The "Hepatocellular Carcinoma - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
Hepatocellular Carcinoma Epidemiology
The Hepatocellular Carcinoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hepatocellular Carcinoma Drug Chapters
This segment of the Hepatocellular Carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Hepatocellular Carcinoma Market Outlook
The Hepatocellular Carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.
- Bayer HealthCare
- Sumitomo Dainippon Pharma
- Bristol-Myers Squibb
- Bayer Pharma
- Eli Lilly and Co.
- Exelixis Inc.
- Tiziana Life Sciences
- CASI Pharmaceuticals
Key Topics Covered:
1. Key Insights
2. Hepatocellular Carcinoma Market Overview at a Glance
3. Disease Background and Overview: Hepatocellular Carcinoma
4. Epidemiology and Patient Population
5. Key Findings
6. Population and Forecast Parameters
7. Country Wise-Epidemiology of HCC
8. Treatment Practices
9. Unmet Needs
10. Marketed Drug Analysis
11. Emerging Therapies
12. Emerging Drugs Analysis
13. Other Promising Candidates
14. Failure in Phase III Clinical trials for Hepatocellular Carcinoma
15. Hepatocellular Carcinoma [HCC]: G8 Countries Market Analysis
16. Key Findings
17. Market Outlook by Country
18. Market Drivers
19. Market Barriers
21. Report Methodology
24. About the Publisher
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8w7n8l/global?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180702005360/en/
SOURCE: Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs
Copyright Business Wire 2018